In a culture of marijuana, autoimmune disease, cannabidiol, cannabidiol (CBD), cannabinoids, Cannabis, Crohn’s disease, the endocannabinoid system, fight against disease with Cannabis, lupus, medical Cannabis, medical marijuana, medical marijuana for topical use, oil of Rick Simpson, Rick Simpson Oil (RSO), dyes, Uncategorized by Eric Harmon, March 12, 2016

Crohn’s disease? I had never heard of it before becoming a medical marijuana patient looking for and studying Rick Simpson Oil (RSO). While using marijuana extract to fight my father’s 4-cell kidney cancer, I ran into some races of young, good-looking female buds that use Cannabis to treat their Crohn, a member of the Syndrome irritable bowel (IBS) group of conditions.

My curiosity was fueled when I learned that my five-year-old niece had “intestinal permeability”. She has been annoyed by a plethora of psoriasis, diarrhoea, fatigue, stomach problems and so on. Then it hit me while I was talking to Jane Fix, head of Patient Services at Monarch Dispensary; that “leaky gut syndrome” can result in and is related to IBS disorders.

What is Crohn’s disease

GI-Trac SATIVAisticatedNamed after Dr Burrill B. Crohn, who first described the disease in 1932 together with Dr Gordon D. Oppenheimer and Dr Leon Ginzburg, Crohn’s disease belongs to a group of conditions known as diseases intestinal inflammation (IBD). Crohn’s is a chronic condition which causes inflammation of the gastrointestinal tract.

When reading about inflammatory bowel disease, it is essential to appreciate that Crohn’s disease is not the same as ulcerative colitis, another form of IBD. The symptoms of these two diseases are quite similar, but the areas affected in the gastrointestinal tract (gastrointestinal tract) are different.

Crohn’s disease most commonly affects the end of the small intestine (the ileum) and the beginning of the colon but can change any area of the (GI) tract. Ulcerative colitis is limited to the colon; also called the large intestine.

Crohn’s disease also affects the thickness of the intestinal wall, while ulcerative colitis involves only the innermost lining of the colon. Finally, in Crohn’s disease, inflammation of the intestine can “jump” – leaving natural areas between the patches of the diseased intestine. In ulcerative colitis, this does not occur.

Clinical evidence shows that Cannabis can be an excellent treatment for Crohn’s disease, and has no adverse side effects.

In ancient medicine, Cannabis had been extensively used to treat intestinal ailments and inflammation. A recent clinical study had shown that the medicinal plant Cannabis sativa has lived up to expectations and has proven highly efficient in cases of inflammatory bowel disease. In a placebo-controlled study, Naftali et al. have shown what has been widely anticipated by anecdotal reports, namely that Cannabis produces significant clinical benefits in patients with Crohn’s disease. The mechanisms involved are not yet precise, but most likely include peripheral actions on cannabinoid receptors 1 and 2 (CB) (CB1 and CB2) and may also include central effects.

The past ten years have seen a steady increase in publications dealing with the anti-inflammatory effects of CBs and the potential underlying mechanisms. Preclinical data on the enhancement effect of synthetic and natural CBs in animal models that mimic the characteristics of IBD have evolved rapidly. The rational idea that CBs would also be useful in IBD patients was based primarily on the results of experiments on CB receptor knockout mice and data using CB receptor agonists and antagonists. 

Following a previous publication of a retrospective, an observational study by Naftali et al. and a questionnaire from a different group in patients with ulcerative colitis and Crohn’s disease, both revealing symptom relief and improvement after cannabis use, Naftali et al. have now presented a prospective placebo-controlled study of 21 Crohn’s disease patients who do not respond to standard IBD treatment.

 Although the primary endpoint of induction of remission has not been statistically achieved, they have been able to demonstrate that 8-week treatment with Cannabis enriched with tetrahydrocannabinol (THC) caused a reduction in the activity index of Crohn’s disease in 90% of patients without producing significant side effects. The authors rightly concluded that a larger group of patients is warranted for future studies.

This is the first clinical study on the effect of Cannabis in IBD and confirms what has long been suggested by experimental studies, namely that CBs can provide anti-inflammatory effects and symptomatic benefits in IBD patients. The physiological support for the beneficial effects of Cannabis was established some time ago and has been unveiled ever since. The discovery of endogenous molecules and CB receptors that activate these receptors led to the description of a coordinated network inherent in the mammalian organism, the endocannabinoid system. 

This comprises of the CB receptors (CB1, CB2), their endogenous ligands anandamide and 2-arachidonoyl glycerol (2-AG), also known as endocannabinoids, and their synthesizing and degrading enzymes. What capsaicin, the potent ingredient of chilli peppers, is for vanilloid receptors and morphine for opioid receptors is TerraHydra-Cannabanoil, the psychedelic ingredient of Cannabis, for CB receptors: the predominant herbal ligand. Therefore, THC mimics activities of anandamide and 2 AG.

The wall of the gastrointestinal tract contains all the components of the endocannabinoid system. Recent data show that these components are expressed differently in human IBD, indicating a regulatory role in disease progression. While anandamide and its synthesizing enzyme show lower levels of ulcerative colitis, the expression of CB2 receptors and proteins responsible for the synthesis and degradation of 2-AG has increased. The results indicate that the CB2 receptor plays a crucial role in the CB enhancing effect in IBD. The precise mechanism on how CBs contribute to IBD improvement, however, is unclear. Still, using experimental models of intestinal inflammation, we can define a picture of how and on what targets CBS cause inflammation improvement.

CB1 and CB2 receptors are found in the colon epithelium, and a protective effect of THC through epithelial permeability is conceivable. Therefore, OCs could improve epithelial wound closure in the colon. One of the main characteristics of CBs in experimental intestinal inflammation is their effect on immunocytes which mainly express CB2 receptors. After activation of CB2, T cells undergo apoptosis and reduced proliferation in colitis. Also, the activation of CB2 reduces the recruitment of neutrophils, T cells and macrophages in the inflamed colon; CB receptors are also detected in the enteric nervous system (ENS), controlling motility and intestinal secretion. The CB1 receptors present in the ENS represent a rupture that protects the ENS from hyperstimulation, a situation easily caused by the overexpression of inflammatory mediators that activate the ENS during IBD. Therefore, activation of CB receptors by THC can reduce the hypermotility associated with inflammation of the intestine. The reduction of hyper-motility can thus alleviate diarrhoea producing beneficial effects for the patient.

Potential objectives and mechanisms of the CBs involved in the improvement of IBD

THE CB1 AND CB2 RECEPTORS ARE LOCATED AT THE COLONIC EPITHELIUM, AND A PROTECTIVE EFFECT OF THC IS EFFECTIVE THROUGH EPITHELIAL PERMEABILITY.

RSO TEAM

It should be stressed that the brain is the leading site of CB1 expression and that the occupancy of CB2 has also been detected in the brain stem. The use of Cannabis to improve inflammation could, therefore, include central effects, such as a reduction in the sensation of pain and relief from nausea and the feeling of unpleasantness. A report suggests that a complete anti-inflammatory CB response in intestinal inflammation includes the central nervous system since a limited peripheral CB1 / CB2 receptor agonist was not useful or too flimsy to improve colitis, depending on the experimental model applied.

In their prospective study, Naftali et al. he used THC-free Cannabis as a placebo without other CBs. However, we should also consider that other cannabis ingredients, such as cannabidiol, cannabigerol and tetrahydrocannabivarin, all non-psychotropic components of Cannabis, have demonstrated anti-inflammatory effects in experimental intestinal inflammation. Their actions partly involve non-CB receptor mechanisms through, for example, peroxisome proliferator-activated receptors (PPAR) and cationic channel subfamily receptors, potential transient receptors (TRPV) and should be considered as additive beneficial effects of the Cannabis in the improvement of colitis in addition to the effects mediated by THC.

In summary, according to the ancient use of Cannabis in intestinal disorders and a decade of animal research, Cannabis has been shown in a clinical study to reduce symptoms in patients with Crohn’s disease. This elegant translation should be followed by more extensive evidence confirming these results and by tests establishing the mechanisms involved in opening a promising direction for the future treatment of IBD. – Source

Cannabinoid treatment

Both THC and CBD cannabinoids have been shown to treat the conditions of irritable bowel syndrome (IBS) and Crohn’s. For the treatment of highly concentrated THC, Rick Simpson Oil (RSO) should be prescribed. The patients I spoke to about their treatment with RSO, each said that they only take one particle size of the extract, i.e. a small amount. Less than a tenth of a gram a day gave everyone great assistance.

Cannabidiol (CBD) has also demonstrated to treat Crohn’s disease and other irritable bowel disorders (IBS). The CBD project has an extensive collection of links to research papers covering cannabidiol and Crohn’s disease. For CBD treatment, concentrated extracts of CBD-rich material are suggested.

For patients who are not smokers but plan to use cannabinoids to treat their Crohn’s disorder or other IBS disorders, a drink could be a good start. There are two paths to go. One is taking only one CBD version, and I would recommend Charlotte’s Web or secondly, one that combines both THC and CBD. For this, we feel that a [THC Cannabis Smoothie would be an excellent starting point.] we have written an article on it, and we are looking into selling drinks. Still, for the time being, we won’t, we do plan to make a video giving instructions on doing so very soon.